Clear all
2020 • MOSAIC: A model to assess the cost-effectiveness of dexamethasone for admitted COVID-19 patients in South Africa
Authors: Cleary, Susan, Tchuem, Cynthia Tamandjou, Geetesh Solanki, Docrat, Sumaiyah, Besada, Donela, Wilkinson, Tommy
Abstract: (...)
MODEL STRATEGIES
This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death.

Two competing strategies are modelled:
1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone).
2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days.
MODEL STRATEGIES
This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death.

Two competing strategies are modelled:
1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone).
2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days.

MODEL OUTCOMES
Cost: mean cost (general ward and ICU) per admitted patient from the health care provider's perspective.
Health outcomes: mean DALYs and deaths per admitted patient.
Other: mean ICU days and inpatient days per admitted patient.
 (Read More)
External links: OpenAIRE

Works in BIP! associated with the specified OpenAIRE research product

We have placed cookies on your device to help make this website and the services we offer better. By using this site, you agree to the use of cookies. Learn more
I accept